OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shiller Discusses Molecular Testing in Gastrointestinal Cancers

August 22nd 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular testing in gastrointestinal cancers.

Dr. Galsky Discusses Neoadjuvant Immunotherapy in Bladder Cancer

August 22nd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immunotherapy in bladder cancer.

Dr. Tolaney Discusses the Role of Chemotherapy in HER2+ Breast Cancer

August 22nd 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the role of chemotherapy in the treatment of patients with HER2-positive breast cancer.

Dr. Powell Discusses Immunotherapy in Ovarian Cancer

August 22nd 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses immunotherapy in ovarian cancer.

Dr. Pacheco on Second-Line Therapy for ALK+ NSCLC

August 21st 2018

Jose M. Pacheco, MD, assistant professor, Medicine/Medical Oncology, Colorado University School of Medicine, discusses second-line therapy for patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Gentzler on the Role of Chemotherapy in Metastatic NSCLC

August 21st 2018

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses the role of chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC).

Dr. Secord on Using Biomarkers to Guide Treatment Decisions in Ovarian Cancer

August 21st 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the use of biomarkers to guide treatment decisions in patients with ovarian cancer.

Dr. Novik on Benefits/Challenges of Implementing Biosimilars

August 21st 2018

Yelena Novik, MD, associate professor, New York University’s Perlmutter Cancer Center, discusses the benefits and challenges of the global implementation of biosimilars.

Dr. Tarhini on Recent Practice-Changing Clinical Trials in Melanoma

August 21st 2018

Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.

Dr. Herzog on the Optimal Use of Bevacizumab in Patients With Ovarian Cancer

August 21st 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the optimal use of bevacizumab (Avastin) in patients with ovarian cancer.

Dr. Paulson on When to Consider Lutathera in Patients With NETs

August 21st 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses when to consider using Lutathera (lutetium Lu 177 dotatate) in patients with neuroendocrine tumors (NETs).

Dr. McCollum on Frontline Therapy for Patients With Metastatic CRC

August 21st 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses frontline therapy for patients with metastatic colorectal cancer (mCRC).

Dr. Ansell Discusses the Role of PD-1 Blockade in Lymphoma

August 20th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Dr. Becerra Discusses Regorafenib Dosing in Metastatic CRC

August 20th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.

Dr. Van Veldhuizen Reflects on the CARMENA Trial in RCC

August 20th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the impact of the CARMENA trial results in renal cell carcinoma.

Dr. Gandara on Treatment Options for Squamous Cell NSCLC

August 20th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, 2017 Giant of Cancer Care in Lung Cancer, discusses treatment options for patients with squamous cell non–small cell lung cancer.

Dr. Desai on Phase I Study of Entrectinib in Solid Tumors

August 20th 2018

Ami Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.

Dr. Lonial on CAR T-Cell Therapy in Myeloma

August 17th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

Dr. Engel on the Future of Eltrombopag in HIV-Related Thrombocytopenia

August 17th 2018

Elissa Engel, MD, pediatric resident, University of South Florida, discusses the future of eltrombopag (Promacta) in HIV-related thrombocytopenia.

Challenges in the Treatment of Patients With MCL

August 17th 2018

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses challenges in the treatment of patients with mantle cell lymphoma (MCL).